

# Ann W Morgan

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7712240/ann-w-morgan-publications-by-year.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

142  
papers

8,173  
citations

46  
h-index

88  
g-index

177  
ext. papers

9,357  
ext. citations

6.9  
avg, IF

4.94  
L-index

#	Paper	IF	Citations
142	A methodological framework for AI-assisted diagnosis of active aortitis using radiomic analysis of FDG PET-CT images: Initial analysis.. <i>Journal of Nuclear Cardiology</i> , <b>2022</b> , 1	2.1	1
141	A High-Throughput Amplicon Screen for Somatic UBA1 Variants in Cytopenic and Giant Cell Arteritis Cohorts.. <i>Journal of Clinical Immunology</i> , <b>2022</b> , 1	5.7	2
140	Association between age at disease onset of anti-neutrophil cytoplasmic antibody-associated vasculitis and clinical presentation and short-term outcomes. <i>Rheumatology</i> , <b>2021</b> , 60, 617-628	3.9	8
139	Transcriptome-wide study of TNF-inhibitor therapy in rheumatoid arthritis reveals early signature of successful treatment. <i>Arthritis Research and Therapy</i> , <b>2021</b> , 23, 80	5.7	2
138	Non-communicable disease, sociodemographic factors, and risk of death from infection: a UK Biobank observational cohort study. <i>Lancet Infectious Diseases</i> , <b>2021</b> , 21, 1184-1191	25.5	13
137	Evaluating tertiary adrenal insufficiency in rheumatology patients on long-term systemic glucocorticoid treatment. <i>Clinical Endocrinology</i> , <b>2021</b> , 94, 361-370	3.4	1
136	Latent Class Trajectory Modeling of 2-Component Disease Activity Score in 28 Joints Identifies Multiple Rheumatoid Arthritis Phenotypes of Response to Biologic Disease-Modifying Antirheumatic Drugs. <i>Arthritis and Rheumatology</i> , <b>2020</b> , 72, 1632-1642	9.5	6
135	Oral glucocorticoids and incidence of hypertension in people with chronic inflammatory diseases: a population-based cohort study. <i>Cmaj</i> , <b>2020</b> , 192, E295-E301	3.5	10
134	Standardized protocols for differentiation of THP-1 cells to macrophages with distinct M(IFN $\beta$ LPS), M(IL-4) and M(IL-10) phenotypes. <i>Journal of Immunological Methods</i> , <b>2020</b> , 478, 112721	2.5	18
133	Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study. <i>PLoS Medicine</i> , <b>2020</b> , 17, e1003432	11.6	34
132	Pharmacogenetics of TNF inhibitor response in rheumatoid arthritis utilizing the two-component disease activity score. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 1151-1156	2.6	1
131	Self-risk assessment for patients with rheumatic disease during the COVID-19 pandemic. <i>Lancet Rheumatology</i> , <b>2020</b> , 2, e386-e387	14.2	1
130	Differential DNA methylation correlates with response to methotrexate in rheumatoid arthritis. <i>Rheumatology</i> , <b>2020</b> , 59, 1364-1371	3.9	24
129	Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study <b>2020</b> , 17, e1003432		
128	Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study <b>2020</b> , 17, e1003432		
127	Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study <b>2020</b> , 17, e1003432		
126	Dose-dependent oral glucocorticoid cardiovascular risks in people with immune-mediated inflammatory diseases: A population-based cohort study <b>2020</b> , 17, e1003432		

125	Association of response to TNF inhibitors in rheumatoid arthritis with quantitative trait loci for and CD39. <i>Annals of the Rheumatic Diseases</i> , <b>2019</b> , 78, 1055-1061	2.4	12
124	Improvement in cardiovascular biomarkers sustained at 4 years following an initial treat-to-target strategy in early rheumatoid arthritis. <i>Rheumatology</i> , <b>2019</b> , 58, 1684-1686	3.9	3
123	A Multicenter, Randomized, Placebo-Controlled Trial of Atorvastatin for the Primary Prevention of Cardiovascular Events in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2019</b> , 71, 1437-1449	9.5	46
122	Validity of a two-component imaging-derived disease activity score for improved assessment of synovitis in early rheumatoid arthritis. <i>Rheumatology</i> , <b>2019</b> ,	3.9	21
121	Dose dependency of iatrogenic glucocorticoid excess and adrenal insufficiency and mortality: a cohort study in England. <i>Journal of Clinical Endocrinology and Metabolism</i> , <b>2019</b> ,	5.6	28
120	Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England. <i>Cmaj</i> , <b>2019</b> , 191, E680-E688	3.5	26
119	Genetic associations with radiological damage in rheumatoid arthritis: Meta-analysis of seven genome-wide association studies of 2,775 cases. <i>PLoS ONE</i> , <b>2019</b> , 14, e0223246	3.7	8
118	Rapid visual recovery following intravenous tocilizumab in glucocorticoid resistant refractory giant cell arteritis. <i>BMJ Case Reports</i> , <b>2019</b> , 12,	0.9	3
117	Cross-phenotype analysis of ImmunoChip data identifies as a relevant for the development of systemic vasculitis. <i>Annals of the Rheumatic Diseases</i> , <b>2018</b> , 77, 589-595	2.4	16
116	Effect of Fatigue, Older Age, Higher Body Mass Index, and Female Sex on Disability in Early Rheumatoid Arthritis in the Treatment-to-Target Era. <i>Arthritis Care and Research</i> , <b>2018</b> , 70, 361-368	4.7	9
115	Affimer proteins inhibit immune complex binding to FcγRIIIa with high specificity through competitive and allosteric modes of action. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , <b>2018</b> , 115, E72-E81	11.5	27
114	Prediction of treatment response in rheumatoid arthritis patients using genome-wide SNP data. <i>Genetic Epidemiology</i> , <b>2018</b> , 42, 754-771	2.6	13
113	A TNFSF13B functional variant is not involved in systemic sclerosis and giant cell arteritis susceptibility. <i>PLoS ONE</i> , <b>2018</b> , 13, e0209343	3.7	3
112	Genome-wide association study of response to tumour necrosis factor inhibitor therapy in rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , <b>2018</b> , 18, 657-664	3.5	32
111	Genome-wide association study of response to methotrexate in early rheumatoid arthritis patients. <i>Pharmacogenomics Journal</i> , <b>2018</b> , 18, 528-538	3.5	25
110	High frequency of antidrug antibodies and association of random drug levels with efficacy in certolizumab pegol-treated patients with rheumatoid arthritis: results from the BRAGGSS cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2017</b> , 76, 208-213	2.4	40
109	Neonatal Behçet disease. <i>Archives of Disease in Childhood</i> , <b>2017</b> , 102, 1062	2.2	
108	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. <i>American Journal of Human Genetics</i> , <b>2017</b> , 100, 64-74	11	43

107	The predictive value of serum S100A9 and response to etanercept is not confirmed in a large UK rheumatoid arthritis cohort. <i>Rheumatology</i> , <b>2017</b> , 56, 1019-1024	3.9	7
106	Achieving consensus on minimum data items (including core outcome domains) for a longitudinal observational cohort study in rheumatoid arthritis. <i>Rheumatology</i> , <b>2017</b> , 56, 550-555	3.9	2
105	Patient-reported Outcomes as Predictors of Change in Disease Activity and Disability in Early Rheumatoid Arthritis: Results from the Yorkshire Early Arthritis Register. <i>Journal of Rheumatology</i> , <b>2017</b> , 44, 1331-1340	4.1	3
104	Detection of anti-drug antibodies using a bridging ELISA compared with radioimmunoassay in adalimumab-treated rheumatoid arthritis patients with random drug levels. <i>Rheumatology</i> , <b>2016</b> , 55, 2050-2055	3.9	10
103	Improvement in insulin resistance is greater when infliximab is added to methotrexate during intensive treatment of early rheumatoid arthritis-results from the IDEA study. <i>Rheumatology</i> , <b>2016</b> , 55, 2181-2190	3.9	18
102	Previously reported PDE3A-SLCO1C1 genetic variant does not correlate with anti-TNF response in a large UK rheumatoid arthritis cohort. <i>Pharmacogenomics</i> , <b>2016</b> , 17, 715-20	2.6	8
101	Description and Validation of Histological Patterns and Proposal of a Dynamic Model of Inflammatory Infiltration in Giant-cell Arteritis. <i>Medicine (United States)</i> , <b>2016</b> , 95, e2368	1.8	32
100	Differential Methylation as a Biomarker of Response to Etanercept in Patients With Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , <b>2016</b> , 68, 1353-60	9.5	46
99	Impact of inadequate adherence on response to subcutaneously administered anti-tumour necrosis factor drugs: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Rheumatology</i> , <b>2015</b> , 54, 494-9	3.9	69
98	Validity and reliability of the Persian version of Behçet's disease quality-of-life (BD-QoL) questionnaire: a cross-cultural adaptation. <i>Rheumatology International</i> , <b>2015</b> , 35, 677-84	3.6	2
97	Association of HLA-DRB1 haplotypes with rheumatoid arthritis severity, mortality, and treatment response. <i>JAMA - Journal of the American Medical Association</i> , <b>2015</b> , 313, 1645-56	27.4	92
96	A large-scale genetic analysis reveals a strong contribution of the HLA class II region to giant cell arteritis susceptibility. <i>American Journal of Human Genetics</i> , <b>2015</b> , 96, 565-80	11	96
95	Clinical utility of random anti-tumour necrosis factor drug testing and measurement of anti-drug antibodies on long-term treatment response in rheumatoid arthritis. <i>Lancet, The</i> , <b>2015</b> , 385 Suppl 1, S48 <sup>40</sup>		12
94	Clinical utility of random anti-tumor necrosis factor drug-level testing and measurement of antidrug antibodies on the long-term treatment response in rheumatoid arthritis. <i>Arthritis and Rheumatology</i> , <b>2015</b> , 67, 2011-9	9.5	69
93	Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis. <i>Nature Communications</i> , <b>2015</b> , 6, 6046	17.4	103
92	Association study of genes related to bone formation and resorption and the extent of radiographic change in ankylosing spondylitis. <i>Annals of the Rheumatic Diseases</i> , <b>2015</b> , 74, 1387-93	2.4	50
91	Association of HLA-DRB1 amino acid residues with giant cell arteritis: genetic association study, meta-analysis and geo-epidemiological investigation. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 195	5.7	25
90	Rheumatoid arthritis response to treatment across IgG1 allotype - anti-TNF incompatibility: a case-only study. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 63	5.7	9

89	Investigating CD11c expression as a potential genomic biomarker of response to TNF inhibitor biologics in whole blood rheumatoid arthritis samples. <i>Arthritis Research and Therapy</i> , <b>2015</b> , 17, 359	5.7	5
88	Curry-assisted diagnosis in the rheumatology clinic. <i>Oxford Medical Case Reports</i> , <b>2015</b> , 2015, 297-9	0.6	0
87	Novel rheumatoid arthritis susceptibility locus at 22q12 identified in an extended UK genome-wide association study. <i>Arthritis and Rheumatology</i> , <b>2014</b> , 66, 24-30	9.5	36
86	Should I send my patient with previous giant cell arteritis for imaging of the thoracic aorta? A systematic literature review and meta-analysis. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 143-8	2.4	51
85	Remission induction comparing infliximab and high-dose intravenous steroid, followed by treat-to-target: a double-blind, randomised, controlled trial in new-onset, treatment-naive, rheumatoid arthritis (the IDEA study). <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 75-85	2.4	106
84	Testing the role of vitamin D in response to antitumour necrosis factor $\alpha$ therapy in a UK cohort: a Mendelian randomisation approach. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 938-40	2.4	6
83	Emergence of proinflammatory autoreactive T-cell responses in preclinical rheumatoid arthritis. <i>Lancet, The</i> , <b>2014</b> , 383, S22	4.0	2
82	Association of a complement receptor 1 gene variant with baseline erythrocyte sedimentation rate levels in patients starting anti-TNF therapy in a UK rheumatoid arthritis cohort: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Pharmacogenomics Journal</i> , <b>2014</b> , 14, 171-5	3.5	3
81	Impact of psychological factors on subjective disease activity assessments in patients with severe rheumatoid arthritis. <i>Arthritis Care and Research</i> , <b>2014</b> , 66, 861-8	4.7	58
80	MTHFR functional genetic variation and methotrexate treatment response in rheumatoid arthritis: a meta-analysis. <i>Pharmacogenomics</i> , <b>2014</b> , 15, 467-75	2.6	15
79	Evidence of NLRP3-inflammasome activation in rheumatoid arthritis (RA); genetic variants within the NLRP3-inflammasome complex in relation to susceptibility to RA and response to anti-TNF treatment. <i>Annals of the Rheumatic Diseases</i> , <b>2014</b> , 73, 1202-10	2.4	128
78	Predicting the risk of rheumatoid arthritis and its age of onset through modelling genetic risk variants with smoking. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003808	6	40
77	Identification of BACH2 and RAD51B as rheumatoid arthritis susceptibility loci in a meta-analysis of genome-wide data. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 3058-62		35
76	Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. <i>PLoS Genetics</i> , <b>2013</b> , 9, e1003394	6	127
75	Allele-dose association of the C5orf30 rs26232 variant with joint damage in rheumatoid arthritis. <i>Arthritis and Rheumatism</i> , <b>2013</b> , 65, 2555-61		17
74	Identification of the PTPN22 functional variant R620W as susceptibility genetic factor for giant cell arteritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 1882-1886	2.4	37
73	Metaanalysis of the association of smoking and PTPN22 R620W genotype on autoantibody status and radiological erosions in rheumatoid arthritis. <i>Journal of Rheumatology</i> , <b>2013</b> , 40, 1048-53	4.1	11
72	In situ macromolecular crystallography using microbeams. <i>Acta Crystallographica Section D: Biological Crystallography</i> , <b>2012</b> , 68, 592-600		109

71	Outrunning free radicals in room-temperature macromolecular crystallography. <i>Acta Crystallographica Section D: Biological Crystallography</i> , <b>2012</b> , 68, 810-8		70
70	Confirmation of association of FCGR3B but not FCGR3A copy number with susceptibility to autoantibody positive rheumatoid arthritis. <i>Human Mutation</i> , <b>2012</b> , 33, 741-9	4.7	32
69	Replication of association of the PTPRC gene with response to anti-tumor necrosis factor therapy in a large UK cohort. <i>Arthritis and Rheumatism</i> , <b>2012</b> , 64, 665-70		55
68	Differential effects of infliximab on absolute circulating blood leucocyte counts of innate immune cells in early and late rheumatoid arthritis patients. <i>Clinical and Experimental Immunology</i> , <b>2012</b> , 170, 36-46	6.2	32
67	Investigation of IL1, VEGF, PPARG and MEFV genes in psoriatic arthritis susceptibility. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 313-4	2.4	11
66	Correlation of C-reactive protein haplotypes with serum C-reactive protein level and response to anti-tumor necrosis factor therapy in UK rheumatoid arthritis patients: results from the Biologics in Rheumatoid Arthritis Genetics and Genomics Study Syndicate cohort. <i>Arthritis Research and Therapy</i> , <b>2012</b> , 14, P211	5.7	16
65	A spectrum of susceptibility to rheumatoid arthritis within HLA-DRB1: stratification by autoantibody status in a large UK population. <i>Genes and Immunity</i> , <b>2012</b> , 13, 120-8	4.4	46
64	Informed conditioning on clinical covariates increases power in case-control association studies. <i>PLoS Genetics</i> , <b>2012</b> , 8, e1003032	6	58
63	Comprehensive assessment of rheumatoid arthritis susceptibility loci in a large psoriatic arthritis cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1350-4	2.4	31
62	Relationship between area-level socio-economic deprivation and autoantibody status in patients with rheumatoid arthritis: multicentre cross-sectional study. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, 1640-5	2.4	15
61	The contribution of genetic risk factors other than the HLA shared epitope alleles to the genetic variance of rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2012</b> , 71, A52.1-A52	2.4	
60	FcRIIIa expression on monocytes in rheumatoid arthritis: role in immune-complex stimulated TNF production and non-response to methotrexate therapy. <i>PLoS ONE</i> , <b>2012</b> , 7, e28918	3.7	42
59	Interaction between ERAP1 and HLA-B27 in ankylosing spondylitis implicates peptide handling in the mechanism for HLA-B27 in disease susceptibility. <i>Nature Genetics</i> , <b>2011</b> , 43, 761-7	36.3	646
58	Genome-wide association study of genetic predictors of anti-tumor necrosis factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. <i>Arthritis and Rheumatism</i> , <b>2011</b> , 63, 645-53		124
57	Evidence to support IL-13 as a risk locus for psoriatic arthritis but not psoriasis vulgaris. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1016-9	2.4	60
56	Confirmation of TNIP1 and IL23A as susceptibility loci for psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 1641-4	2.4	93
55	Genetic variants within the MAP kinase signalling network and anti-TNF treatment response in rheumatoid arthritis patients. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 98-103	2.4	48
54	Cardiovascular risk and rheumatoid arthritis--the next step: differentiating true soluble biomarkers of cardiovascular risk from surrogate measures of inflammation. <i>Rheumatology</i> , <b>2011</b> , 50, 1944-54	3.9	26



53	Study of the common genetic background for rheumatoid arthritis and systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , <b>2011</b> , 70, 463-8	2.4	107
52	Ischaemic manifestations in giant cell arteritis are associated with area level socio-economic deprivation, but not cardiovascular risk factors. <i>Rheumatology</i> , <b>2011</b> , 50, 2014-22	3.9	22
51	Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. <i>Nature</i> , <b>2010</b> , 464, 713-20	50.4	639
50	Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. <i>Nature Genetics</i> , <b>2010</b> , 42, 508-14	36.3	969
49	Dissection of the FCGR3A association with RA: increased association in men and with autoantibody positive disease. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1054-7	2.4	52
48	Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. <i>Human Molecular Genetics</i> , <b>2010</b> , 19, 4544-4544	5.6	78
47	PADI4 genotype is not associated with rheumatoid arthritis in a large UK Caucasian population. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 666-70	2.4	57
46	No evidence for association of the KLF12 gene with rheumatoid arthritis in a large UK cohort. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1407-8	2.4	4
45	Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy. <i>Rheumatology</i> , <b>2010</b> , 49, 1894-9	3.9	21
44	Association between anti-tumour necrosis factor treatment response and genetic variants within the TLR and NF $\kappa$ B signalling pathways. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1315-20	2.4	59
43	Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis. <i>Rheumatology</i> , <b>2010</b> , 49, 43-7	3.9	8
42	Investigation of rheumatoid arthritis susceptibility genes identifies association of AFF3 and CD226 variants with response to anti-tumour necrosis factor treatment. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1029-35	2.4	78
41	Variants in linkage disequilibrium with the late cornified envelope gene cluster deletion are associated with susceptibility to psoriatic arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 2199-203	2.4	35
40	Association of CD40 with rheumatoid arthritis confirmed in a large UK case-control study. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 813-6	2.4	49
39	Evaluation of the rheumatoid arthritis susceptibility loci HLA-DRB1, PTPN22, OLIG3/TNFAIP3, STAT4 and TRAF1/C5 in an inception cohort. <i>Arthritis Research and Therapy</i> , <b>2010</b> , 12, R57	5.7	32
38	Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. <i>Arthritis Research and Therapy</i> , <b>2010</b> , 12, R175	5.7	79
37	Polymorphisms spanning the TNFR2 and TACE genes do not contribute towards variable anti-TNF treatment response. <i>Pharmacogenetics and Genomics</i> , <b>2010</b> , 20, 338-41	1.9	10
36	Confirmation of association of the REL locus with rheumatoid arthritis susceptibility in the UK population. <i>Annals of the Rheumatic Diseases</i> , <b>2010</b> , 69, 1572-3	2.4	23

35	Rheumatoid arthritis risk allele PTPRC is also associated with response to anti-tumor necrosis factor alpha therapy. <i>Arthritis and Rheumatism</i> , <b>2010</b> , 62, 1849-61		74
34	Angiogenesis and Giant Cell Arteritis <b>2010</b> , 383-402		0
33	Identification of AF4/FMR2 family, member 3 (AFF3) as a novel rheumatoid arthritis susceptibility locus and confirmation of two further pan-autoimmune susceptibility genes. <i>Human Molecular Genetics</i> , <b>2009</b> , 18, 2518-22	5.6	70
32	Combined effects of three independent SNPs greatly increase the risk estimate for RA at 6q23. <i>Human Molecular Genetics</i> , <b>2009</b> , 18, 2693-9	5.6	77
31	Association of rheumatoid factor and anti-cyclic citrullinated peptide positivity, but not carriage of shared epitope or PTPN22 susceptibility variants, with anti-tumour necrosis factor response in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 69-74	2.4	210
30	Investigating the viability of genetic screening/testing for RA susceptibility using combinations of five confirmed risk loci. <i>Rheumatology</i> , <b>2009</b> , 48, 1369-74	3.9	15
29	Reevaluation of the interaction between HLA-DRB1 shared epitope alleles, PTPN22, and smoking in determining susceptibility to autoantibody-positive and autoantibody-negative rheumatoid arthritis in a large UK Caucasian population. <i>Arthritis and Rheumatism</i> , <b>2009</b> , 60, 2565-76		79
28	Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. <i>Nature Genetics</i> , <b>2009</b> , 41, 1313-8	36.3	272
27	A re-evaluation of three putative functional single nucleotide polymorphisms in rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2009</b> , 68, 1373-5	2.4	13
26	Investigation of genetic variants within candidate genes of the TNFRSF1B signalling pathway on the response to anti-TNF agents in a UK cohort of rheumatoid arthritis patients. <i>Pharmacogenetics and Genomics</i> , <b>2009</b> , 19, 319-23	1.9	26
25	Rheumatoid arthritis susceptibility loci at chromosomes 10p15, 12q13 and 22q13. <i>Nature Genetics</i> , <b>2008</b> , 40, 1156-9	36.3	125
24	Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. <i>Human Molecular Genetics</i> , <b>2008</b> , 17, 3532-8	5.6	96
23	Re-evaluation of putative rheumatoid arthritis susceptibility genes in the post-genome wide association study era and hypothesis of a key pathway underlying susceptibility. <i>Human Molecular Genetics</i> , <b>2008</b> , 17, 2274-9	5.6	121
22	Copy number of FCGR3B, which is associated with systemic lupus erythematosus, correlates with protein expression and immune complex uptake. <i>Journal of Experimental Medicine</i> , <b>2008</b> , 205, 1573-82	16.6	183
21	A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis. <i>QJM - Monthly Journal of the Association of Physicians</i> , <b>2008</b> , 101, 299-306	2.7	9
20	The shared epitope hypothesis in rheumatoid arthritis: evaluation of alternative classification criteria in a large UK Caucasian cohort. <i>Arthritis and Rheumatism</i> , <b>2008</b> , 58, 1275-83		35
19	Rheumatoid arthritis association at 6q23. <i>Nature Genetics</i> , <b>2007</b> , 39, 1431-3	36.3	328
18	Asthma and airways collapse in two heritable disorders of connective tissue. <i>Annals of the Rheumatic Diseases</i> , <b>2007</b> , 66, 1369-73	2.4	37



17	The requirement for DNAM-1, NKG2D, and NKp46 in the natural killer cell-mediated killing of myeloma cells. <i>Cancer Research</i> , <b>2007</b> , 67, 8444-9	10.1	243
16	Association of FCGR2A and FCGR2A-FCGR3A haplotypes with susceptibility to giant cell arteritis. <i>Arthritis Research and Therapy</i> , <b>2006</b> , 8, R109	5.7	40
15	Analysis of Fcγ receptor haplotypes in rheumatoid arthritis: FCGR3A remains a major susceptibility gene at this locus, with an additional contribution from FCGR3B. <i>Arthritis Research and Therapy</i> , <b>2006</b> , 8, R5	5.7	34
14	Interleukin-7 deficiency in rheumatoid arthritis: consequences for therapy-induced lymphopenia. <i>Arthritis Research</i> , <b>2005</b> , 7, R80-92		58
13	Analysis of the insertion/deletion related polymorphism within T cell antigen receptor beta variable genes in primary Sjögren's syndrome. <i>Annals of the Rheumatic Diseases</i> , <b>2005</b> , 64, 468-70	2.4	7
12	Diagnosing late onset rheumatoid arthritis, polymyalgia rheumatica, and temporal arteritis in patients presenting with polymyalgic symptoms. A prospective longterm evaluation. <i>Journal of Rheumatology</i> , <b>2005</b> , 32, 1043-6	4.1	40
11	Fcγ receptors are critical modulators of inflammation within the synovium: comment on the article by Blom et al. <i>Arthritis and Rheumatism</i> , <b>2004</b> , 50, 1352-3; author reply 1353-4		
10	FcγRIIIA-158V and rheumatoid arthritis: a confirmation study. <i>British Journal of Rheumatology</i> , <b>2003</b> , 42, 528-33		40
9	Association of Fcγ receptor IIIA polymorphism with rheumatoid arthritis: comment on the article by Morgan et al. <i>Arthritis and Rheumatism</i> , <b>2002</b> , 46, 556-9		3
8	Unique TCR beta-subunit variable gene haplotypes in Africans. <i>Immunogenetics</i> , <b>2002</b> , 53, 884-93	3.2	3
7	Dysregulated lymphocyte proliferation and differentiation in patients with rheumatoid arthritis. <i>Blood</i> , <b>2002</b> , 100, 4550-6	2.2	127
6	Human immunodeficiency virus associated spondyloarthropathy: pathogenic insights based on imaging findings and response to highly active antiretroviral treatment. <i>Annals of the Rheumatic Diseases</i> , <b>2001</b> , 60, 696-8	2.4	25
5	Does the shared epitope genotype influence either the susceptibility to or the phenotype of corneal melting?. <i>Eye</i> , <b>2001</b> , 15, 492-6	4.4	5
4	Le jeu et le travail thérapeutique direct avec le nourrisson. <i>Devenir</i> , <b>2001</b> , 13, 5	0.5	
3	Fcγ receptor type IIIA is associated with rheumatoid arthritis in two distinct ethnic groups. <i>Arthritis and Rheumatism</i> , <b>2000</b> , 43, 2328-34		93
2	Laboratory findings and pathology of psoriatic arthritis. <i>Baillieres Clinical Rheumatology</i> , <b>1994</b> , 8, 439-63		6
1	Non-communicable disease and the risk of infection death: a UK Biobank prospective cohort study		1